Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.54 |
| ▸ | BRAF | P15056 | 5/20 | 0.54 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296483 | 0.88 | RAF1 (0.56) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL2299028 | 0.87 | RAF1 (0.57) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL2357595 | 0.86 | RAF1 (0.56) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL2301431 | 0.85 | RAF1 (0.54) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL1469078 | 0.85 | RAF1 (0.45) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL3856725 | 0.81 | RAF1 (0.37) | RAF1BRAFLMNACYP2C9MAPT | |
| SCHEMBL2299280 | 0.81 | RAF1 (0.57) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL2300130 | 0.80 | RAF1 (0.57) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL2299292 | 0.80 | RAF1 (0.55) | RAF1BRAFABL1LMNACYP2C9 | |
| SCHEMBL3471881 | 0.80 | RAF1 (0.59) | RAF1BRAFABL1LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | claimed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |